---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-331994"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2021-11-17T23:59:59+00:00"
generated_at: "2026-06-28T07:21:08.657541+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Apellis Pharmaceuticals prices $350M public offering of 8.75M shares at $40/share

## Summary
- Apellis priced public offering of 8.75M shares at $40.00/share for gross proceeds of $350M.
- Underwriters have 30-day option to purchase up to 1.3125M additional shares at the same price less discounts.
- Estimated net proceeds of ~$330.2M, or ~$379.8M if underwriters fully exercise option.
- Offering expected to close Nov. 18, 2021; J.P. Morgan, Goldman Sachs, Evercore are joint book-running managers.

## SEC filing metadata
- accession: 0001193125-21-331994
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2021-11-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312521331994/0001193125-21-331994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312521331994/d222547d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-331994
- JSON: https://secwatch.observer/filing/0001193125-21-331994.json
- Plain text: https://secwatch.observer/filing/0001193125-21-331994.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.